Amgen Value Stock - Dividend - Research Selection
Market price: 245,35 USD
Amgen Fundamental data and company key figures of the share
|Annual reports in USD|
|Net operating cash flow||9.261.000.000|
|Free cash flow||8.381.000.192|
|Liabilities & Shareholders equity||61.165.000.000|
|Diluted shares outstanding||570.000.000|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Market Capitalization||139.849.498.624,00 USD|
|Indices||Dow Jones Industrial Average,MSCI World Index,NASDAQ 100,NASDAQ Comp.,S&P 500|
|Raw Data Source||US GAAP in Millionen USD|
|Stock Split||1999-11-22,2.0000/1.0000; 1999-03-01,2.0000/1.0000; 1995-08-16,2.0000/1.0000; 1991-09-11,3.0000/1.0000; 1990-08-13,2.0000/1.0000|
Description of the company
Amgen Inc. is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics. Its medicines help millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis (RA), bone disease, and other serious illnesses. On December 10, 2012, the Company acquired all of the outstanding stock of deCODE Genetics (deCODE). In July 5, 2012, the Company acquired KAI Pharmaceuticals, a privately held company based in South San Francisco. In September 2013, Swedish Orphan Biovitrum AB (publ) (Sobi) announced that they have acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen Inc for all therapeutic indications.